Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
(New York, NY) May 14, 2013-The theme of the third annual US-China Pharma Conference is "Shrewd Strategies for Mining Profits from Pharma Opportunities in China" and takes place May 20-21 at Harvard Medical School in Boston, MA. Presented by conference organizers Cypin Productions, the conference will address the expanding marketplace in China for the US pharmaceutical industry. With expenditures for healthcare and drugs in China expected to reach $1 trillion by 2020, this timely conference will bring together key strategists and opinion leaders in the pharmaceutical industry, as well as consultants, in discussions and networking sessions about how to source, build and maintain sustainable profit growth over the long term in China.
Throughout the conference, presentations will highlight trends and solutions in drug discovery and intellectual property. Keynote speakers and panelists include senior level experts in the fields of CRO's, R&D, venture capital, academia, biotechnology and pharmaceuticals. Talks and forums will focus on case studies, market analysis, commercialization, licensing, technology transfer, pricing, reimbursement, regulatory affairs, clinical development and strategic alliances. Some of the companies participating include WUXI AppTec, Bristol-Myers Squibb, Crystal Pharmatech, Dr. Reddy's, Pfizer, HUYA Bioscience, Bayer, Biogen Idec, Dana-Farber Cancer Institute, Vanderbilt University, and Jacobs Wyper Architects, bringing a full circle from drug discovery to drug manufacturing facilities and labs.
"In this ground-breaking US-China Pharma Conference, our objectives are to reveal and identify profit potentials and the strategies needed to achieve these profits," explained Judy Tsui, Conference Director. "One of the growing concerns is how to shrewdly adapt to China's new healthcare system where intellectual property issues are becoming challenging at every level of developing, pricing and marketing biosimilar products," added Tsui. Cypin Production works to build bridges between emerging markets.
The first day opens with Seizing China's Pharma Opportunities: The Roadmap to 2020. The topics that will be addressed during the program are:
• IP Protection, Innovation Transfer and Commercialization;
• Innovative Models and Approaches to Capture Opportunities in China;
• Emerging Licensing Opportunities in China;
• Current State and Future of the Chinese Pharma Market: The New Healthcare Reform;
• Changing Approaches to Research and Development.
Among the highlights of this year's conference is the live presentation on May 21 at 1:30pm (EST) of G. Steve Burrill on the Outlook on Pharma in Emerging Markets which will be moderated by one of the leading editors in pharmaceutical publishing, William Looney, of Pharmaceutical Executive.
"We continue to see a steady increase of business in the China pharmaceutical industry," said Robert Wenslow, Director of Business Development, Crystal Pharmatech, and former scientist at Merck. "What appears to be lacking is a dedication to both fundamental and applied industrial science. Getting a drug to market takes more than fancy equipment and an endless labor pool. Words, websites, and trade shows fail to showcase the understanding and perseverance it takes to successfully develop a new chemical entity," continued Wenslow. Crystal Pharmatech, a leader in a group of small CRO's, was founded less than three years ago on these principles by a group of scientists mostly from Merck. Crystal Pharmatech provides "cradle to market" drug development needs.
Based on the success of last year's conference, there are more ways to gain knowledge and network for added value. For example, participants can schedule private one-on-one meetings with potential partners and practitioners of preclinical and clinical development from North America, China and Europe. A speed networking session and private dinner with government officials, investors and industry leaders is scheduled during the two-day conference. In addition, a cocktail reception will bring together students from Harvard Medical School, members of Massbio, as well as other locally based biopharma executives.
According to Cypin Production, the organizer of the conference, the opportunity for synergy and growth provided by this conference is invaluable. "While major developed markets for biopharmaceuticals and life sciences will grow just 3 to 6 percent through 2014, emerging markets are expected to grow to between 14 and 17 percent," added Tsui. "One of these especially vital and growing markets in biopharma is China."
For more information on US-China Pharma, or to register for the conference, which takes place at Joseph Martin Conference Center, Harvard Medical Center, 77 Avenue Louis Pasteur, please visit http://www.chinarndpartnership.com/
Crystal Pharmatech, headquartered in Suzhou, China with an office in Princeton, NJ, is a technology-driven CRO that offers materials research service for active pharmaceutical ingredients and formulations used in drug discovery. It provides its customers with data derived from experiments and also partners with clients to ensure comprehensive solutions for their research needs based on sound scientific understanding. www.crystalpharmatech.com
Help employers find you! Check out all the jobs and post your resume.